Article
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Journal of gastroenterology and hepatology - 1 Nov 2016
Wei Lai, Zhang Mingxiang, Xu Min, Chuang Wan-Long, Lu Wei, Xie Wen, Jia Zhansheng, Gong Guozhong, Li Yueqi, Bae Si Hyun, Yang Yong-Feng, Xie Qing, Lin Shumei, Chen Xinyue, Niu Junqi, Jia Jidong, Garimella Tushar, Torbeyns Anne, McPhee Fiona, Treitel Michelle, Yin Philip D, Mo Ling
Abstract excerpt
BACKGROUND AND AIM: Daclatasvir plus asunaprevir has demonstrated efficacy and safety in patients with chronic hepatitis C virus genotype 1b infection. This study focused on evaluating daclatasvir plus asunaprevir in interferon (±ribavirin)-ineligible or -intolerant Asian patients with genotype 1b infection from mainland China, Korea, and Taiwan. METHODS: Interferon (±ribavirin)-ineligible and -intolerant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.